Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitorSix abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the